Shares of Pacira BioSciences (NASDAQ:PCRX) were sinking 12.7% as of 3:33 p.m. EDT on Monday. The decline came after the company announced that eVenus Pharmaceutical Laboratories is seeking Food and Drug Administration approval for a generic version of non-opioid pain drug Exparel.
The possibility of generic competition for Exparel presents a key challenge for Pacira. In the second quarter, the drug generated $130.1 million of the company’s total $135.6 million in sales. It’s not surprising, therefore, that the pharma stock took a big hit today.
But investors shouldn’t put the cart before the horse here. So far, eVenus has only filed an Abbreviated New Drug Application (ANDA) with the FDA. The company is challenging the validity of Pacira’s patent. But that patent represents only one of several pending patents that Pacira thinks could extend its marketing position for Exparel into the 2040s.
Pacira stated in a press release that it’s “currently assessing” the notice letter it received related to eVenus’ ANDA filing. The company has 45 days to initiate legal action against eVenus for patent infringement. It seems likely that’s the course that Pacira will take, considering the company’s statement that it “intends to vigorously defend its intellectual property rights relating to Exparel.”
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.